Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT01427244
First received: August 31, 2011
Last updated: June 12, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)